NCT02601313 2026-03-18
ZUMA-2
Gilead Sciences
Phase 2 Completed
Clinical Trials
8 trialsNCT05537766 2026-03-10
ZUMA-25
Gilead Sciences
Phase 2 Terminated
NCT06144606 2026-02-09
Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06553872 2026-02-09
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT03642626 2026-01-23
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
Masonic Cancer Center, University of Minnesota
Phase 2 Active not recruiting
NCT06213311 2026-01-14
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06253663 2025-12-16
JKART-1
Gilead Sciences
Phase 2 Active not recruiting
NCT04880434 2025-11-17
ZUMA-2
Gilead Sciences
Phase 2 Completed